MartinMarkowitzMD

Infectious Disease • New York, NY

Clinical Director and Staff Investigator ADARC Aaron Diamond Professor at the Rockefeller U.

Join to view full profile

Dr. Markowitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Markowitz's full profile

Already have an account?

Office
455 1st Ave
7th Floor Aaron Diamond Aids Research Center
New York, NY 10016
Phone+1 212-448-5020

Fax+1 212-725-1126
Is this information wrong?

Education & Training

NYU Grossman School of MedicineFellowship, Infectious Disease, 1991 - 1994
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1981 - 1984
University of California (San Francisco)/Mount ZionResidency, Internal Medicine, 1978 - 1980
Stanford University School of MedicineClass of 1978

Certifications & Licensure

NY State Medical License 1981 - 2025
FL State Medical License 1990 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years
Completed
Phase 1
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
Completed
Not Applicable
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV Start of enrollment: 2004 Feb 01
Completed
Phase 2
Long-term Follow-up of HIV Infected Patients Identified During Early Infection Start of enrollment: 2003 Jul 01
Completed
Observational Study of Treated and Untreated Acute and Early HIV-1 Infection Start of enrollment: 2002 Feb 01
Completed
Phase I/II, Open-Label Trial of Three Monoclonal Antibodies Start of enrollment: 2003 Oct 01
Completed
Phase 1, Phase 2
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) Start of enrollment: 2007 Oct 01
Completed
Not Applicable
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc Start of enrollment: 2007 Sep 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

10 citations
Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1.
Nicolas Vabret, Valérie Najburg, Alexander Solovyov, Ramya Gopal, Christopher McClain, Petr Šulc, Sreekumar Balan, Yannis Rahou, Guillaume Beauclair, Maxime Chazal, Hu...> ;Iscience. 2022 Jul 15
25 citations
Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3.
Martin Markowitz, Agegnehu Gettie, Leslie St. Bernard, Chasity D. Andrews, Hiroshi Mohri, Amir Horowitz, Brooke Grasperge, James Blanchard, Tao Niu, Li Sun, Kerry L. F...> ;The Journal of Infectious Diseases. 2020 Apr 7
51 citations
Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
Mansi Saxena, Rachel Lubong Sabado, Melissa La Mar, Hiroshi Mohri, Andres M. Salazar, Hanqing Dong, Joel Correa da Rosa, Martin Markowitz, Nina Bhardwaj, Elizabeth M. ...> ;Frontiers in Immunology. 2019 Apr 9
45 citations
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Miranda Murray, Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Krischan J Hudson, Britt Stancil, Susan L. Ford, Parul Patel, Alex R. Rinehart, William...> ;HIV Clinical Trials. 2018 Nov 16
66 citations
4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.
Martin Markowitz, Stefan G. Sarafianos> ;Current Opinion in HIV and AIDS. 2018 Jul 1
47 citations
Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.
Martin Markowitz, Howard A Grossman, Peter L. Anderson, Robert M. Grant, Monica Gandhi, Howard Horng, Hiroshi Mohri> ;Journal of Acquired Immune Deficiency Syndromes. 2017 Dec 1
148 citations
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Richard Elion, Deborah Goldstein, Chester Fisher, Magdalena E. Sobieszczyk, Joel E. Gallant, Hong Van T...> ;The Lancet. HIV. 2017 Aug 1
8 citations
Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic.
Natalie N. Kinloch, Daniel MacMillan, Anh Q. Le, Laura A. Cotton, David R. Bangsberg, Susan Buchbinder, Mary Carrington, Jonathan D. Fuchs, P. Richard Harrigan, Beryl ...> ;Journal of Virology. 2016 Feb 1
17 citations
Behavioural, Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug Users.
Saurabh Mehandru, Sherry Deren, Sung-Yeon Kang, Angela Banfield, Aakash Garg, Donald Garmon, Melissa LaMar, Teresa H. Evering, Martin Markowitz> ;Journal of Addiction Research & Therapy. 2015 Dec 31
77 citations
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
Chasity D. Andrews, Yun Lan Yueh, William Spreen, Leslie St. Bernard, Mar Boente-Carrera, Kristina Rodriguez, Agegnehu Gettie, Kasi E. Russell-Lodrigue, James Blanchar...> ;Science Translational Medicine. 2015 Jan 14
71 citations
High Interest in a Long-Acting Injectable Formulation of Pre-Exposure Prophylaxis for HIV in Young Men Who Have Sex with Men in NYC: A P18 Cohort Substudy
Kathrine Meyers, Kristina Rodriguez, Robert W. Moeller, Ilana Gratch, Martin Markowitz, Perry N. Halkitis> ;Plos One. 2014 Dec 11
105 citations
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
Joseph J. Eron, David A. Cooper, Roy T. Steigbigel, Bonaventura Clotet, José M. Gatell, Princy Kumar, Jürgen K. Rockstroh, Mauro Schechter, Martin Markowitz, Patrick Y...> ;The Lancet. Infectious Diseases. 2013 Jul 1
40 citations
Next-generation integrase inhibitors : where to after raltegravir?
Sharon L. Karmon, Martin Markowitz> ;Drugs. 2013 Feb 15
28 citations
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
Martin Markowitz, Florin Vaida, C. Bradley Hare, Daniel Boden, Hiroshi Mohri, Frederick Hecht, Robert C. Kalayjian, Ann Conrad, Donna Mildvan, Judith A. Aberg, Christi...> ;The Journal of Infectious Diseases. 2010 May 1
92 citations
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
Martin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, Fernando Mendo, Winai Ratanasuwan, Colin Kovacs, Guillermo Prada, Javier O Morales-Ramirez, Clyde S. Crumpacker, Ro...> ;Journal of Acquired Immune Deficiency Syndromes. 2009 Nov 1
Elite Suppressor-Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics
Benhur Lee, Martin Markowitz, Robert F Siliciano, Michael A Lobritz> ;PLoS One.
16 citations
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2...
Martin Markowitz, Leonard N. Slater, Robert S. Schwartz, Powel Kazanjian, Bruce Hathaway, David Wheeler, Mitchell Goldman, Dietmar Neubacher, Douglas L. Mayers, Hernan...> ;Journal of Acquired Immune Deficiency Syndromes. 2007 Aug 1
43 citations
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-n...
Martin Markowitz, Christina Hill-Zabala, Joseph Lang, Edwin DeJesus, Qiming Liao, E. Randall Lanier, E. Anne Davis, Mark S. Shaefer> ;Journal of Acquired Immune Deficiency Syndromes. 2005 Jul 1
132 citations
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.
Martin Markowitz, Hiroshi Mohri, Saurabh Mehandru, Anita Shet, Leslie Berry, Roopa Kalyanaraman, Alexandria Kim, Chris Chung, Patrick Jean-Pierre, Amir Horowitz, Melis...> ;Lancet. 2005 Mar 19
840 citations
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.
Mehandru, S., Poles, M. A., Tenner-Racz, K., Horowitz, A., Hurley, A., Hogan, C., Boden, D., Racz, P., Markowitz, M.> ;The Journal of experimental medicine. 2004 Sep 15
271 citations
A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo
Martin Markowitz, Michael Louie, Arlene Hurley, Eugene Sun, Michele Di Mascio, Alan S. Perelson, David D. Ho> ;Journal of Virology. 2003 Apr 15
122 citations
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
Martin Markowitz, Xia Jin, Arlene Hurley, Viviana Simon, Bharat Ramratnam, Michael Louie, Geoffrey R. Deschenes, Murugappan Ramanathan, Shady Barsoum, Jeroen Vanderhoe...> ;The Journal of Infectious Diseases. 2002 Sep 1
161 citations
The Effect of Commencing Combination Antiretroviral Therapy Soon after Human Immunodeficiency Virus Type 1 Infection on Viral Replication and Antiviral Immune Responses
Martin Markowitz, Mika Vesanen, Klara Tenner-Racz, Yunzhen Cao, James M. Binley, Andrew H. Talal, Arlene Hurley, Xia Ji, M. Rashid Chaudhry, Melody Yaman, Sarah S. Fra...> ;The Journal of Infectious Diseases. 1999 Mar 1
118 citations
A Preliminary Evaluation of Nelfinavir Mesylate, an Inhibitor of Human Immunodeficiency Virus (HIV)-1 Protease, to Treat HIV Infection
Martin Markowitz, Marcus A. Conant, Arlene Hurley, Rosemary Schluger, Margarita Duran, Joanna Peterkin, Sharon Chapman, Amy Patick, Amy Hendricks, Geoffrey J. Yuen, Wi...> ;The Journal of Infectious Diseases. 1998 Jun 1
Join now to see all

Press Mentions

HIV Eradication Goals Stuck Between Perfect and RealisticJanuary 3rd, 2019